MaxCyte (MXCT) has released an update.
MaxCyte Inc., a prominent player in cell-engineering technologies, has disclosed that John Johnston, a Non-Executive Director, exercised options for 3,000 shares and subsequently sold them at prices ranging from $4.630 to $4.790 each. This transaction, conducted under a pre-arranged trading plan, represents a minor change in Johnston’s holdings, which post-sale include 120,583 shares and additional stock options and restricted units.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
